Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout

Summary

This safety and feasibility, open-label study of up to 9 subjects will examine a group of subjects with poorly controlled tophaceous gout (intolerant to or ineffective oral urate lowering agents and loss of prior Pegloticase response) pre-treated with Rituximab to recapture response to Methotrexate-Pegloticase.

Timeline

Start

2024-04-10

Primary completion

2024-11-22

Completion

2024-11-22

Drugs

Indications